1. Dwyer, MG, Bergsland, N, Ramasamy, DP, et al. Atrophied brain lesion volume : A new imaging biomarker in multiple sclerosis. J Neuroimaging 2018; 28(5): 490–495.
Google Scholar | Crossref | Medline2. Frohman, EM, Racke, MK, Raine, CS. Multiple sclerosis: The plaque and its pathogenesis. N Engl J Med 2006; 354(9): 942–955.
Google Scholar | Crossref | Medline | ISI3. The International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium 2 . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.
Google Scholar | Crossref | Medline | ISI4. Bellou, V, Belbasis, L, Tzoulaki, I, et al. Environmental risk factors and multiple sclerosis: An umbrella review of meta-analyses. Lancet Neurol 2015; 14(3): 263–273.
Google Scholar | Crossref | Medline5. Munger, KL, Bentzen, J, Laursen, B, et al. Childhood body mass index and multiple sclerosis risk: A long-term cohort study. Mult Scler 2013; 19(10): 1323–1329.
Google Scholar | SAGE Journals | ISI6. Langer-Gould, A, Brara, SM, Beaber, BE, et al. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80(6): 548–552.
Google Scholar | Crossref | Medline7. Munger, KL, Chitnis, T, Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 2009; 73(19): 1543–1550.
Google Scholar | Crossref | Medline | ISI8. Hedström, AK, Olsson, T, Alfredsson, L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18(9): 1334–1336.
Google Scholar | SAGE Journals | ISI9. Engin, A . The pathogenesis of obesity-associated adipose tissue inflammation. Adv Exp Med Biol 2017; 960: 221–245.
Google Scholar | Crossref | Medline10. Kappos, L, Polman, CH, Freedman, MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67(7): 1242–1249.
Google Scholar | Crossref | Medline | ISI11. Kappos, L, Freedman, MS, Polman, CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : A 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.
Google Scholar | Crossref | Medline | ISI12. Kappos, L, Freedman, MS, Polman, CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8(11): 987–997.
Google Scholar | Crossref | Medline | ISI13. Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis : Guidelines for research protocols. Ann Neurol 1983; 13(3): 227–231.
Google Scholar | Crossref | Medline | ISI14. McDonald, WI, Compston, A, Edan, G, et al. Recommended diagnostic criteria for multiple sclerosis : Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121–127.
Google Scholar | Crossref15. Thompson, AJ, Banwell, BL, Barkhof, F, et al. Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162–173.
Google Scholar | Crossref | Medline | ISI16. Vine, M, Hulka, B, Margolin, B, et al. Cotinine concentrations in semen, urine, and blood of smokers and nonsmokers. Am J Public Health 1993; 83(9): 1335–1338.
Google Scholar | Crossref | Medline17. Barkhof, F, Polman, C, Radue, E, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: Integrated 2-year results. Arch Neurol 2007; 64(9): 1292–1298.
Google Scholar | Crossref | Medline18. Zivadinov, R, Reder, A, Filippi, M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71(2): 136–144.
Google Scholar | Crossref | Medline19. Bliss, CI . Periodic regression in biology and climatology (No. 615). New Haven, CT: Connecticut Agricultural Experiment Station, 1958, pp. 3–55.
Google Scholar20. Munger, KL, Levin, LI, Holls, BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296(23): 2832–2838.
Google Scholar | Crossref | Medline | ISI21. Manouchehrinia, A, Hedström, AK, Alfredsson, L, et al. Association of pre-disease body mass index with multiple sclerosis prognosis. Front Neurol 2018; 9: 232.
Google Scholar | Crossref | Medline22. Tettey, P, Simpson, S, Taylor, B, et al. An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. J Neurol Neurosurg Psychiatry 2017; 88(5): 395–401.
Google Scholar | Crossref | Medline23. Mowry, EM, Azevedo, CJ, Mcculloch, CE, et al. Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology 2018; 91(24): e2256–e2264.
Google Scholar | Crossref | Medline24. Bove, R, Musallam, A, Xia, Z, et al. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Mult Scler Relat Disord 2016; 8: 136–140.
Google Scholar | Crossref | Medline25. Kvistad, SS, Myhr, K-M, Holmøy, T, et al. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol 2015; 288: 92–97.
Google Scholar | Crossref | Medline26. Munger, KL, Fitzgerald, KC, Freedman, MS, et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 2015; 85(19): 1694–1701.
Google Scholar | Crossref | Medline27. Castro, K, Ntranos, A, Amatruda, M, et al. Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course. EBioMedicine 2019; 43: 392–410.
Google Scholar | Crossref | Medline28. Bobb, J, Schwartz, B, Davatzikos, C, et al. Cross-sectional and longitudinal association of body mass index and brain volume. Hum Brain Mapp 2014; 35(1): 75–88.
Google Scholar | Crossref | Medline